CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects.
Trends Mol Med
; 27(1): 7-10, 2021 01.
Article
en En
| MEDLINE
| ID: mdl-33129692
Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antagonizing CGRP in COVID-19. Awareness regarding potential cardiopulmonary adverse effects may enable their early detection and prevent illness from worsening.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Receptores de Péptido Relacionado con el Gen de Calcitonina
/
Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina
/
SARS-CoV-2
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
/
Cardiopatías
Tipo de estudio:
Screening_studies
Límite:
Animals
/
Humans
Idioma:
En
Año:
2021
Tipo del documento:
Article